Dysregulated Tyrosine Kinase Signaling in Leukemia

Dysregulated Tyrosine Kinase Signaling in Leukemia


Lead sponsor: University of New Mexico

Source University of New Mexico
Brief Summary

Dysregulated Tyrosine Kinase Signaling in Leukemia

Detailed Description

Purpose: to look at a number of proteins in the abnormal cells in the blood and/or bone marrow. These proteins make a cell grow or prevent the cell from dying

Overall Status Completed
Start Date May 2002
Completion Date October 2005
Primary Completion Date October 2005
Study Type Observational
Enrollment 30

Sampling method: Non-Probability Sample


Inclusion Criteria:

- Patients must have newly diagnosed or relapsed leukemia.

- Patients must sign an informed consent.

- Patients will not be excluded if they are receiving chemotherapy.

- Patients with CML, AML, ALL, T/NK leukemia, myelodysplasia, or myeloproliferative disorders will be eligible.

- Patients must be => 18 years of age.

Gender: All

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Overall Official
Last Name Role Affiliation
Ian Rabinowitz, MD Principal Investigator University of New Mexico
facility University of New Mexico
Location Countries

United States

Verification Date

April 2008

Responsible Party

Name title: Ian Rabinowitz, MD

Organization: University of New Mexico CRTC

Has Expanded Access No
Condition Browse
Study Design Info

Observational model: Cohort

Time perspective: Prospective

Source: ClinicalTrials.gov